Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance.

ABSTRACT:

Background

Although significant advances have been made recently to characterize the biology of pancreatic ductal adenocarcinoma (PDAC), more efforts are needed to improve our understanding and to face challenges related to the aggressiveness, high mortality rate and chemoresistance of this disease.

Methods

In this study, we perform the metabolomics profiling of 77 PDAC patient-derived tumor xenografts (PDTX) to investigate the relationship of metabolic profiles with overall survival (OS) in PDAC patients, tumor phenotypes and resistance to five anticancer drugs (gemcitabine, oxaliplatin, docetaxel, SN-38 and 5-Fluorouracil).

Findings

We identified a metabolic signature that was able to predict the clinical outcome of PDAC patients (p < 0.001, HR=2.68 [95% CI: 1.5-4.9

SUBMITTER: Kaoutari AE 

PROVIDER: S-EPMC8054161 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature